121986-03-6

Basic information

• Product Name: α-(4-cyanophenyl)-α-hydroxyacetonitrile
• CAS NO: 121986-03-6
• Molecular Weight: 158.159
• Mol File: 121986-03-6.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: α-(4-cyanophenyl)-α-hydroxyacetonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: α-(4-cyanophenyl)-α-hydroxyacetonitrile(121986-03-6)
• EPA Substance Registry System: α-(4-cyanophenyl)-α-hydroxyacetonitrile(121986-03-6)

Safety Data

• Hazardous Substances Data: 121986-03-6(Hazardous Substances Data)

Upstream product

• 75-86-5 2-hydroxy-2-methylpropanenitrile 
• 105-07-7 4-cyanobenzaldehyde 
• 613-90-1 benzoyl cyanide 
• 74-90-8 hydrogen cyanide 
• 7677-24-9 trimethylsilyl cyanide 
• 73183-24-1 2-(4-cyanophenyl)-2-(trimethylsilyloxy)acetonitrile 
• 773837-37-9 sodium cyanide 

Downstream Products

• 52798-36-4 methyl α-(4-cyanophenyl)-α-hydroxyacetate 
• 129803-29-8 4-Cyanocarbonyl-benzonitrile 
• 105-07-7 4-cyanobenzaldehyde 
• 619-65-8 4-cyanobenzoic Acid 
• 1259933-42-0 cyano(4-cyanophenyl)methyl pivalate 
• 876-31-3 4-(cyanomethyl)benzonitrile 

Relevant articles and documents

SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1

The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Synthesis of dichlorophenyl-, cyanophenyl-and quinolinyl-substituted α-ethoxyacetic acids and derivatives, via α-hydroxyarylacetic acids

A synthetic approach to novel series of α-ethoxy-α-phenylacetamides and α-ethoxy-α-quinolinylacetamides was developed. Aryl aldehydes were converted to cyanohydrins, which were then hydrolyzed or alcoholyzed. Following ethylation of the α-hydroxy group, p

Cyanosilylation of aldehydes and ketones catalyzed by nanocrystalline magnesium oxide

Cyanosilylation of various aldehydes and ketones with TMSCN proceeded smoothly under mild conditions to give the corresponding cyanohydrin trimethylsilyl ethers in the presence of nanocrystalline magnesium oxide. The cyanohydrin trimethylsilyl ethers of aldehydes produced cyanohydrins in good to high yields on treatment with 2 N HCl. 29Si NMR spectral evidence proved that the reaction proceeds through the hypervalent silicate species by coordination to O2-/O- (Lewis basic site) of nanocrystalline magnesium oxide. Copyright Taylor & Francis Group, LLC.